A Novel Germline Mutation in Exon 15 of the APC Gene in Attenuated Familial Adenomatous Polyposis: A Report of Two Cases

Jaehoon Jahng, Sang Jin Yoon, and Hyojin Park

Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Attenuated familial adenomatous polyposis (AFAP) is a variant of familial adenomatous polyposis with fewer than one hundred colorectal polyps and a later age of onset of the cancer. Here, we report two cases of AFAP within family members. Each patient demonstrated the same novel germ line mutation in exon 15 of the adenomatous polyposis coli (APC) gene and was successfully managed with sulindac after refusal to perform colectomy: a 23-year-old man with incidentally diagnosed gastric adenoma and fundic gland polyps underwent colonoscopy, and fewer than 100 colorectal polyps were found; a 48-year-old woman who happened to be the mother of the 23-year-old man also showed fewer than 100 colorectal polyps on colonoscopy. Genetic analysis revealed a novel frameshift mutation in exon 15 of the APC gene. The deletion of adenine-guanine with the insertion of thymine in c.3833-3834 resulted in the formation of stop codon 1,287 in both patients. The patients were treated with sulindac due to their refusal to undergo colectomy. The annual follow-up upper endoscopy and colonoscopy in the following 2 years revealed significant regression of the colorectal polyps in both patients. (Gut Liver 2013;7:120-125)

Key Words: Attenuated familial adenomatous polyposis; Mutation; APC; Exon 15

INTRODUCTION

Attenuated familial adenomatous polyposis (AFAP) is a milder variant of familial adenomatous polyposis (FAP), which manifests with fewer than hundred colorectal polyps, later age of onset of polyposis and cancer, and a predilection toward involvement of the proximal colon in clusters.\(^1\)\(^\text{-}^6\)

Much of mutations in AFAP have already been reported.\(^4\)\(^\text{-}^9\) Infrequently few mutations are still being discovered around the world. Herein, we report two cases of same novel germline mutation in the adenomatous polyposis coli (APC) gene of AFAP patients within family members who were treated with sulindac after they refuse to perform colectomy.

CASE REPORTS

1. Case 1

A 23-year-old man with no previous medical history and incidentally discovered multiple gastric polyps was referred to Gangnam Severance Hospital. The patient had gastric tubular adenoma with dysplasia in the antrum of the stomach. Endoscopic submucosal dissection (ESD) was performed for the gastric adenoma in the antrum, and multiple biopsies were done for the variable sized polyps in the upper body and fundus (Fig. 1A and B). Final pathologic report showed tubular adenoma with low grade dysplasia for the antral lesion (Fig. 1C). The colorectal polyps confirmed as tubular adenoma with low grade dysplasia on pathologic report (Fig. 1D-F). Colonic polyps close or equal to 5 mm in size were endoscopically removed using polypectomy snare. Genetic analysis using polymerase chain reaction (PCR) denaturing high performance liquid chromatography and direct sequencing revealed a novel frameshift mutation in the exon 15 of the APC gene. Deletion of adenine-guanine (AG) and insertion of thymine (T) in codon 3833-3834 resulted in the formation of stop codon 1287 (c.3833-3834delAGinsT) (Table 1, Fig. 2).

2. Case 2

The patient’s 48-year-old mother also performed upper endoscopy and colonoscopy. Upper endoscopy showed multiple...
gastric polyps in the fundus and upper body. Pathologic examination confirmed them as fundic gland polyps (Fig. 3A and B). Multiple colonic polyps of 2 to 5 mm size were detected from ascending to sigmoid colon on colonoscopy (Fig. 3C and D). Colon polyps close or equal to 5 mm in size were polypectomized and confirmed as tubular adenoma with low-grade dysplasia. The patient’s sibling died of lymphoma but there was no history of colorectal cancer in the first degree relatives. Genetic analysis also revealed same novel frameshift mutation in the exon 15 of the APC gene with deletion of AG and insertion of T in codon 3833-3834 resulting in the formation of stop codon in 1287 (c.3833-3834delAGinsT) which was identical to the son in the mother (Table 2, Fig. 4). Evaluation with abdomen computerized tomography revealed no demonstrable malignancy in both patients. Both patients were treated with sulindac 200 mg daily, as chemoprophylaxis after they refused to undergo colectomy.

Annual follow-up upper endoscopy for surveillance showed no evidence of recurrence at the site of previous ESD for 2 consecutive years. Colorectal polyps were much regressed in the first year and maintained that way in the second year on follow-up colonoscopy in both patients. Most of the polyps in the ascending, transverse, and descending colon were regressed, and only a few diminutive, sessile polyps were remaining in the rectum after sulindac treatment (Fig. 3E and F).

**DISCUSSION**

Germline mutation in the APC gene located on chromosome 5q21 or in some cases, biallelic mutation in the MutY homologue (MYH) gene are responsible for classic FAP. Like classic FAP, APC mutations in AFAP are likely to be frameshift or single base pair changes that result in premature stop codons and...

---

**Table 1.** Frameshift Mutation of c.3833-3834 in Exon 15 with the Deletion of Adenine-Guanine and the Insertion of Thymine in the Son

| Gene | Exon | Nucleotide change | Amino acid change | Zygosity | Mutation type |
|------|------|------------------|------------------|----------|---------------|
| APC  | 4 (int 3) | c.423-16insT | | Hetero | P |
|      | 15    | c.3833-3834delAGinsT | Ser1275fs | Hetero | FS |
|      | 15    | c.4479G>A | Thr1493Thr | Homo | P |

P, polymorphism; FS, frameshift mutation.
Mutations at the 5' end of APC have been reported as both the first and most frequently encountered mutations related to AFAP. Mutations at the 3' end, exon 9, or intron 9 of APC have also been reported to be the cause of AFAP. Infrequently, mutations of MYH gene located in chromosome 1p32-34 is associated with development of AFAP with variable phenotypic expressions.

The classic FAP is characterized by early onset of numerous colonic adenomas, with inevitable progression to colorectal cancer. Other manifestations include gastroduodenal polyps, desmoid tumors, and extraintestinal features such as congenital hypertrophy of the retinal pigment epithelium, osteoma, and other malignancies. Absolute life time risk of extracolonic cancer range from 0.6% in gastric to 15% in desmoids tumors. Strict endoscopic surveillance is recommended for FAP patients and those who are at risk family members and the optimal treatment remains to be prophylactic colectomy.

On the other hand, AFAP is much subtle in presentation with less than hundred colorectal polyps, delayed onset of colorectal cancer and death compared with FAP. Due to its right side preference and tendency for rectal sparing, colonoscopy is preferred to sigmoidoscopy for surveillance. Even though there are some expectations that the prognosis of AFAP is better than FAP, the risk of missing early colorectal cancer during surveillance and limited knowledge of the risk and prognosis in AFAP still favors prophylactic colectomy with ileorectal anastomosis as standard option. Surveillance for AFAP is different from that of FAP. Since there has been no case reported of colorectal cancer in AFAP under age of 20 years, full colonoscopy is recommended starting from age 18 to 20 years in contrast to 10 to 12 years in FAP with an interval of 2 years.

There are reports of higher cumulative probability of cancer-

---

**Fig. 2.** Frameshift mutation in exon 15 of the adenomatous polyposis coli (APC) gene with the deletion of codon 3833-3844 (c.3833-3834delAGinsT), as detected by polymerase chain reaction and direct sequencing, in the son.

**Fig. 3.** Upper endoscopy and colonoscopy images of the mother. (A) Multiple fundic gland polyps in the fundus and upper body of the stomach. (B) Slightly dilated oxyntic glands of the fundic gland polyps taken from the gastric fundus (H&E stain, ×200). (C) Multiple colonic polyps ranging up to 2 to 5 mm in size on colonoscopy. (E, F) Nearly diminished colonic polyps 1 year after treatment with sulindac.
free survival in AFAP compared to classic FAP even though its intra-familial heterogeneity and phenotypic expression. Mounting evidence supports that endoscopic management with polypectomy might be sufficient enough to manage AFAP. Recently, certain nonsteroidal antiinflammatory drugs are used to prevent polyp progression in patient with AFAP. A Japanese study done with sulindac reduced colorectal adenomas of protruding type in uncolectomized FAP, and its effect is unrelated to the locus of APC mutations. Other more recent report showed regression of polyps in long term treatment with cyclooxygenase-2 inhibitor in a patient with AFAP. A Japanese study done with sulindac reduced colorectal adenomas of protruding type in uncolectomized FAP, and its effect is unrelated to the locus of APC mutations. Other more recent report showed regression of polyps in long term treatment with cyclooxygenase-2 inhibitor in a patient with AFAP. A Japanese study done with sulindac reduced colorectal adenomas of protruding type in uncolectomized FAP, and its effect is unrelated to the locus of APC mutations. Other more recent report showed regression of polyps in long term treatment with cyclooxygenase-2 inhibitor in a patient with AFAP. A Japanese study done with sulindac reduced colorectal adenomas of protruding type in uncolectomized FAP, and its effect is unrelated to the locus of APC mutations. Other more recent report showed regression of polyps in long term treatment with cyclooxygenase-2 inhibitor in a patient with AFAP. A Japanese study done with sulindac reduced colorectal adenomas of protruding type in uncolectomized FAP, and its effect is unrelated to the locus of APC mutations. Other more recent report showed regression of polyps in long term treatment with cyclooxygenase-2 inhibitor in a patient with AFAP. A Japanese study done with sulindac reduced colorectal adenomas of protruding type in uncolectomized FAP, and its effect is unrelated to the locus of APC mutations. Other more recent report showed regression of polyps in long term treatment with cyclooxygenase-2 inhibitor in a patient with AFAP. A Japanese study done with sulindac reduced colorectal adenomas of protruding type in uncolectomized FAP, and its effect is unrelated to the locus of APC mutations. Other more recent report showed regression of polyps in long term treatment with cyclooxygenase-2 inhibitor in a patient with AFAP. A Japanese study done with sulindac reduced colorectal adenomas of protruding type in uncolectomized FAP, and its effect is unrelated to the locus of APC mutations. Other more recent report showed regression of polyps in long term treatment with cyclooxygenase-2 inhibitor in a patient with AFAP.
with high grade dysplasia or large fundic gland polyps (>7 mm), but further study is obviously needed to confirm these assertions.\(^{30}\)

In conclusion, we report a novel germline mutation in codon 3833-3834 at exon 15 of the APC gene of AFAP which were detected in both mother and son. High risk polyps were treated with endoscopic polypectomies in the colon in both patients, and remaining small polyps were managed with the treatment of sulindac. Consequently, it would be reasonable to have them under strict surveillance and chemoprophylaxis to control further growth of polyps, and hopefully regress them. Considering between son’s young age versus the possibility of benign phenotypic expression in some AFAP mutations, early prophylactic colectomy is still a standard treatment option, as well as in the case of the mother, but sulindac has shown satisfactory results as an alternative treatment after they refused to go colectomy. Further investigations for the optimal treatment of AFAP according to genotypic and phenotypic difference are needed.

**CONFLICTS OF INTEREST**

No potential conflict of interest relevant to this article was reported.

**REFERENCES**

1. Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum Mutat 1994;3:121-125.
2. Bussey HJ. Historical developments in familial polyposis coli. Semin Surg Oncol 1987;3:67-70.
3. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006;101:385-398.
4. Knudsen AL, Bisgaard ML, Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003;2:43-55.
5. Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 2002;45:127-134.
6. Young J, Simms LA, Tarish J, et al. A family with attenuated familial adenomatous polyposis due to a mutation in the alternatively spliced region of APC exon 9. Hum Mutat 1998;11:450-455.
7. van der Luijt RB, Vasen HF, Tops CM, Breukel C, Fodde R, Meera Khan P. APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. Hum Genet 1995;96:705-710.
8. Varesco L, Gismondi V, Presciuttini S, et al. Mutation in a splice-donor site of the APC gene in a family with polyposis and late age of colonic cancer death. Hum Genet 1994;93:281-286.
9. Raoof M, Canter RJ, Patsy PB. Variable phenotypic expression of identical MYH germine mutations in siblings with attenuated familial adenomatous polyposis. Am Surg 2007;73:1250-1253.
10. Lynch HT, Smyrk TC. Classification of familial adenomatous polyposis: a diagnostic nightmare. Am J Hum Genet 1998;62:1288-1289.
11. Giardiello FM, Offerhaus JG. Phenotype and cancer risk of various polyposis syndromes. Eur J Cancer 1995;31A:1085-1087.
12. Sturt NJ, Gallagher MC, Bassett P, et al. Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 2004;53:1832-1836.
13. Contessini-Avesani E, Botti F, Negri C, et al. Familial adenomatous polyposis. Surgical treatment: when and how. Tech Coloproctol 2004;8 Suppl 2:S309-S314.
14. Soravia C, Berk T, Madlensky L, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998;62:1290-1301.
15. Vasen HF. Clinical diagnosis and management of hereditary colorectal cancer syndromes. J Clin Oncol 2000;18[21 Suppl]:S15-92S.
16. Vasen HF, Mösllein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008;57:704-713.
17. Giardiello FM, Brensinger JD, Luce MC, et al. Phenotypic expression of disease in families that have mutations in the 5′ region of the adenomatous polyposis coli gene. Ann Intern Med 1997;126:514-519.
18. Esaki M, Matsumoto T, Mizuno M, et al. Effect of sulindac treatment for attenuated familial adenomatous polyposis with a new germline APC mutation at codon 161: report of a case. Dis Colon Rectum 2002;45:1397-1402.
19. Matsumoto T, Nakamura S, Esaki M, Yao T, Iida M. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis. J Gastroenterol Hepatol 2006;21(1 Pt 2):251-257.
20. Ferguson CB, Porter KG, Murphy SJ. Nine-year follow-up of a patient with attenuated familial adenomatous polyposis treated with cyclo-oxygenase-2 inhibitors. Scand J Gastroenterol 2008;43:1534-1536.
21. Bhatnagar P, Tetzlaff H, Izatt L, Devlin J, Heaton ND. Variation of a variation: case report of attenuated familial adenomatous polyposis syndromes. Eur J Cancer 1995;31A:1085-1087.
22. Hofgärtner WT, Thorp M, Ramus MW, et al. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol 1999;94:2275-2281.
23. Beaton MD, Taylor B, Driman D, Ainsworth P, Adams PC. Colonic interposition in a woman with attenuated familial adenomatous polyposis: does the location of the colon affect polyp formation? Can J Gastroenterol 2008;22:634-636.
24. Su LK, Kohlmann W, Ward PA, Lynch PM. Different familial adenomatous polyposis phenotypes resulting from deletions of the entire APC exon 15. Hum Genet 2002;111:88-95.
25. Nieuwenhuis MH, Bülow S, Björk J, et al. Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery. Dis Colon Rectum 2009;52:1259-1263.

26. Nielsen M, Bik E, Hes FJ, et al. Genotype-phenotype correlations in 19 Dutch cases with APC gene deletions and a literature review. Eur J Hum Genet 2007;15:1034-1042.

27. Sieber OM, Lamlum H, Crabtree MD, et al. Whole-gene APC deletions cause classical familial adenomatous polyposis, but not attenuated polyposis or “multiple” colorectal adenomas. Proc Natl Acad Sci U S A 2002;99:2954-2958.

28. Park JG, Park KJ, Ahn YO, et al. Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. Dis Colon Rectum 1992;35:996-998.

29. Garrean S, Hering J, Saied A, Jani J, Espat NJ. Gastric adenocarcinoma arising from fundic gland polyps in a patient with familial adenomatous polyposis syndrome. Am Surg 2008;74:79-83.

30. Zwick A, Munir M, Ryan CK, et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997;113:659-663.